Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
99.6M
-
Number of holders
-
441
-
Total 13F shares, excl. options
-
89.6M
-
Shares change
-
+234K
-
Total reported value, excl. options
-
$8.46B
-
Value change
-
+$8.43M
-
Put/Call ratio
-
0.95
-
Number of buys
-
195
-
Number of sells
-
-245
-
Price
-
$94.30
Significant Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) as of Q2 2023
529 filings reported holding NBIX - NEUROCRINE BIOSCIENCES INC - Common Stock as of Q2 2023.
NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) has 441 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 89.6M shares
of 99.6M outstanding shares and own 89.98% of the company stock.
Largest 10 shareholders include BlackRock Inc. (13.5M shares), VANGUARD GROUP INC (9.57M shares), STATE STREET CORP (3.96M shares), Bellevue Group AG (2.61M shares), JPMORGAN CHASE & CO (1.96M shares), JANUS HENDERSON GROUP PLC (1.91M shares), MORGAN STANLEY (1.87M shares), ARMISTICE CAPITAL, LLC (1.65M shares), RENAISSANCE TECHNOLOGIES LLC (1.64M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.52M shares).
This table shows the top 441 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.